is there any vaccine for it?
Yes. There is a Vaccine called Meningococcus
Meningitis
Meningococcus vaccines exist against groups A, B, C, W135 and Y. In countries where the vaccine for meningococcus group C was introduced, cases caused by this pathogen have decreased substantially. A quadrivalent vaccine now exists, which combines four vaccines with the exception of B; immunization with this ACW135Y vaccine is now a visa requirement for taking part in Hajj. Development of a vaccine against group B meningococci has proved much more difficult, as its surface proteins (which would normally be used to make a vaccine) only elicit a weak response from the immune system, or cross-react with normal human proteins. 
where is the brain located in a human body It is located in and protected by the skull bones of the Head what type of researches are being carried on it? Research has been ongoing to study on How the Brain works. how does it process the language? Language is processed through a wider network of the Cortical regions. how does it deal with emotions? The amygdala, orbitofrontal cortex, mid and anterior insula cortex and lateral prefrontal cortex, appeared to be involved in generating the emotions where as basal ganglia is responsible in happiness, the subcallosal cingulate cortex in sadness, and amygdala in fear. what relation does mind have with brain? Finding the relationship between the two has been a challenge due to the difficulty in explaining how mental activities, such as thoughts and emotions, can be implemented by physical structures such as neurons and synapses, or by any other type of physical mechanism. can you mention a few diseases related to it? Alzheimer's, Parkinson's and Meningitis to name a few. what does third disease refer to? It is an Acute inflammation of the Protective Membranes covering the Brain and Spinal cord. how is it caused? Typically caused by an Infection with microorganisms, viruses and bacteria among others.
wiki:20616116
Meningitis [SEP] Vaccination
Two new vaccines, both approved in 2014, are effective against a wider range of group B meningococci strains. In Africa, until recently, the approach for prevention and control of meningococcal epidemics was based on early detection of the disease and emergency reactive mass vaccination of the at-risk population with bivalent A/C or trivalent A/C/W135 polysaccharide vaccines, though the introduction of MenAfriVac (meningococcus group A vaccine) has demonstrated effectiveness in young people and has been described as a model for product development partnerships in resource-limited settings. Routine vaccination against "Streptococcus pneumoniae" with the pneumococcal conjugate vaccine (PCV), which is active against seven common serotypes of this pathogen, significantly reduces the incidence of pneumococcal meningitis.